Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
A combination of mTOR inhibitor, ridaforolimus and novel AKT inhibitor, MK-2206, showed activity in heavily pretreated hormone positive and negative breast cancer patients who exhibit PI3K pathway dependence, based on low RAS signature score. The combination was well tolerated in a phase I study, according to Dr Shilpa Gupta of the Lee Moffitt Cancer Center, Tampa, USA.
Read the article in full here.
Source: ESMO
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.